| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Science Applications International Corporation-Frederick, Inc., and 2 Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland
Requests for reprints: Giovanni Melillo, Developmental Therapeutics Program, Tumor Hypoxia Laboratory, National Cancer Institute at Frederick, Building 432, Room 218, Frederick, MD 21702. Phone: 301-846-5050; Fax: 301-846-6081; E-mail: melillog{at}ncifcrf.gov.
The identification of small molecules that inhibit the sequence-specific binding of transcription factors to DNA is an attractive approach for regulation of gene expression. Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that controls genes involved in glycolysis, angiogenesis, migration, and invasion, all of which are important for tumor progression and metastasis. To identify inhibitors of HIF-1 DNA-binding activity, we expressed truncated HIF-1
and HIF-1ß proteins containing the basic-helix-loop-helix and PAS domains. Expressed recombinant HIF-1
and HIF-1ß proteins induced a specific DNA-binding activity to a double-stranded oligonucleotide containing a canonical hypoxia-responsive element (HRE). One hundred twenty-eight compounds previously identified in a HIF-1targeted cell-based high-throughput screen of the National Cancer Institute 140,000 small-molecule library were tested in a 96-well plate ELISA for inhibition of HIF-1 DNA-binding activity. One of the most potent compounds identified, echinomycin (NSC-13502), a small-molecule known to bind DNA in a sequence-specific fashion, was further investigated. Electrophoretic mobility shift assay experiments showed that NSC-13502 inhibited binding of HIF-1
and HIF-1ß proteins to a HRE sequence but not binding of the corresponding proteins to activator protein-1 (AP-1) or nuclear factor-
B (NF-
B) consensus sequences. Interestingly, chromatin immunoprecipitation experiments showed that NSC-13502 specifically inhibited binding of HIF-1 to the HRE sequence contained in the vascular endothelial growth factor (VEGF) promoter but not binding of AP-1 or NF-
B to promoter regions of corresponding target genes. Accordingly, NSC-13502 inhibited hypoxic induction of luciferase in U251-HRE cells and VEGF mRNA expression in U251 cells. Our results indicate that it is possible to identify small molecules that inhibit HIF-1 DNA binding to endogenous promoters.
This article has been cited by other articles:
![]() |
G.-M. Zou and A. Maitra Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration Mol. Cancer Ther., July 1, 2008; 7(7): 2012 - 2021. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Peixoto, Y. Liu, S. Depauw, M.-P. Hildebrand, D. W. Boykin, C. Bailly, W. D. Wilson, and M.-H. David-Cordonnier Direct inhibition of the DNA-binding activity of POU transcription factors Pit-1 and Brn-3 by selective binding of a phenyl-furan-benzimidazole dication Nucleic Acids Res., June 1, 2008; 36(10): 3341 - 3353. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Li, L. Chen, F. Yi, M. Xia, and P.-L. Li Salt-Sensitive Hypertension Induced by Decoy of Transcription Factor Hypoxia-Inducible Factor-1{alpha} in the Renal Medulla Circ. Res., May 9, 2008; 102(9): 1101 - 1108. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Lin, C. A. David, J. B. Donnelly, M. Michaelides, N. S. Chandel, X. Huang, U. Warrior, F. Weinberg, K. V. Tormos, S. W. Fesik, et al. A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation PNAS, January 8, 2008; 105(1): 174 - 179. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-S. Park, W.-S. Shin, and S.-K. Kim In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother., January 1, 2008; 61(1): 163 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rapisarda and G. Melillo HIF-1 Inhibitors: Novel Opportunities for Cancer Therapy ASCO Educational Book, January 1, 2008; 2008(1): 543 - 547. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Turcotte and A. J. Giaccia Targeted Therapy for the Loss of the Tumor Suppressor Gene von Hippel-Lindau through Synthetic Lethality ASCO Educational Book, January 1, 2008; 2008(1): e15 - e18. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Sutphin, D. A. Chan, J. M. Li, S. Turcotte, A. J. Krieg, and A. J. Giaccia Targeting the Loss of the von Hippel-Lindau Tumor Suppressor Gene in Renal Cell Carcinoma Cells Cancer Res., June 15, 2007; 67(12): 5896 - 5905. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Cairns, I. Papandreou, P. D. Sutphin, and N. C. Denko Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy PNAS, May 29, 2007; 104(22): 9445 - 9450. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Creighton-Gutteridge, J. H. Cardellina II, A. G. Stephen, A. Rapisarda, B. Uranchimeg, K. Hite, W. A. Denny, R. H. Shoemaker, and G. Melillo Cell Type-Specific, Topoisomerase II-Dependent Inhibition of Hypoxia-Inducible Factor-1{alpha} Protein Accumulation by NSC 644221 Clin. Cancer Res., February 1, 2007; 13(3): 1010 - 1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Nickols, C. S. Jacobs, M. E. Farkas, and P. B. Dervan Improved nuclear localization of DNA-binding polyamides Nucleic Acids Res., January 28, 2007; 35(2): 363 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Li, F. Yi, C. M. Sundy, L. Chen, M. L. Hilliker, D. K. Donley, D. B. Muldoon, and P.-L. Li Expression and actions of HIF prolyl-4-hydroxylase in the rat kidneys Am J Physiol Renal Physiol, January 1, 2007; 292(1): F207 - F216. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Melillo Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy Mol. Cancer Res., September 1, 2006; 4(9): 601 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Pacary, H. Legros, S. Valable, P. Duchatelle, M. Lecocq, E. Petit, O. Nicole, and M. Bernaudin Synergistic effects of CoCl2 and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells J. Cell Sci., July 1, 2006; 119(13): 2667 - 2678. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Melillo and G. L. Semenza Meeting Report: Exploiting the Tumor Microenvironment for Therapeutics. Cancer Res., May 1, 2006; 66(9): 4558 - 4560. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Cairns, I. Papandreou, and N. Denko Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor Microenvironment Mol. Cancer Res., February 1, 2006; 4(2): 61 - 70. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |